English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 12 September 2017, 22:37 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017

TOKYO, Sept 12, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 as the first global SRI indices in the world and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. This year, the DJSI Asia Pacific has selected 152 companies leading the way in sustainability (72 of which are from Japan) from among the region's top 614 companies. Eisai received high scores particularly in categories such as Codes of Business Conduct, Product Quality and Recall Management, Labor Practice Indicators as well as Strategy to Improve Access to Drugs or Products.

In addition to the DJSI Asia Pacific, Eisai has been selected for the 16th consecutive year since 2002 as a member of the FTSE4Good Index Series, another global benchmark SRI index.

The Eisai Group's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
Nov 20, 2017 14:50 HKT/SGT
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Nov 20, 2017 14:28 HKT/SGT
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
Nov 17, 2017 15:00 HKT/SGT
エーザイ、ドイツにおいて公的医療保険中央連合会との合意に基づき、抗てんかん剤「Fycompa(R)」の販売を12月に再開
Nov 6, 2017 19:37 HKT/SGT
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
Nov 6, 2017 11:00 HKT/SGT
エーザイ、第10回アルツハイマー病臨床試験会議(CTAD)にてaducanumabの臨床第Ib相試験の長期継続投与に関する最新データを発表
Oct 31, 2017 12:05 HKT/SGT
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
Oct 31, 2017 11:00 HKT/SGT
エーザイ: 中国で抗がん剤「レンバチニブ」の肝細胞がんに係る適応による新薬承認申請が受理
Oct 31, 2017 11:00 HKT/SGT
エーザイ、第10回アルツハイマー病臨床試験会議(CTAD)において、最新の知見を発表
Oct 31, 2017 10:27 HKT/SGT
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
Oct 24, 2017 10:08 HKT/SGT
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
More news >>
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: